EFC (I)
|
|
| BOM : 512008     NSE : EFCIL     | |
| LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Jun 25,2026 |
|
Price(EOD): ₹ 186.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Business Support |
| MCap: ₹ 2,755.38 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| EFC (I) | -2.4% | 1.6% | -36.8% |
| SAGILITY | 1.8% | -3.2% | -0.6% |
| SYNGENE INTERNATIONAL | -1.1% | -6.3% | -29.3% |
| PRIME FOCUS | -9.5% | -12.8% | 79.2% |
| INTERNATIONAL GEMOLOGICAL INSTITUTE | 1.1% | -5.7% | 1.5% |
| INDEGENE | -2.5% | 0.3% | -8.1% |
| NESCO | -4.3% | -12.1% | 10.2% |
| LATENT VIEW ANALYTICS | -0.4% | -5.7% | -26.1% |
| SUN PHARMA ADVANCED RESEARCH COMPANY | -5.5% | -4.3% | 50.8% |
FUNDAMENTAL ANALYSIS OF EFC (I)
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF EFC (I)
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
11.74
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 234.71 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 3.41
P/B Calculated based on Book Value of Rs 807.25 Cr
[Latest Year - Mar2026 - Consolidated Results ] 2.66
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,036.68 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-16% -52% -64% |
SHARE PRICE MOMENTUM OF EFC (I)
EFC (I) vs SENSEX
DEBT OF EFC (I)
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0 0 0.02 0.01 |
0.43 0.27 0.83 0.51 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF EFC (I)
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF EFC (I)
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
8.64% 28.54% 3.24% 10.33% |
38.8% 31.35% 20.46% 43.56% |
| QtrlyTrend |
8 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
EFC (I) related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE SERVICES | 1.8% | 6.5% | 9.2% |
You may also like the below Video Courses
FAQ about EFC (I)
Is EFC (I) good for long term investment?
As on Jun 25,2026, the Fundamentals of EFC (I) look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of EFC (I) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is EFC (I) UnderValued or OverValued?
As on Jun 25,2026, EFC (I) is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of EFC (I) ?
As on Jun 25,2026, the Intrinsic Value of EFC (I) is Rs. 386.85 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 221.05
Fair Value [Median EV / Sales Model] : Rs. 386.85
Fair Value [Median Price / Sales Model] : Rs. 518.19
Estimated Median Fair Value of EFC (I) : Rs. 386.85
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is EFC (I) trading at a Premium or Discount?
As on Jun 25,2026, EFC (I) is trading at a Discount of -52% based on the estimates of Median Intrinsic Value!SAGILITY LTD vs SYNGENE INTERNATIONAL LTD vs PRIME FOCUS LTD
INTERNATIONAL GEMOLOGICAL INSTITUTE LTD vs INDEGENE LTD vs NESCO LTD